Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

SIMPLE SUMMARY: Bone marrow fibrosis (BMF) is a hallmark of myelofibrosis (a rare blood cancer), and BMF severity may be useful in predicting patient response to treatment, since high-severity BMF is associated with poor survival. In this study, we studied how BMF severity and early (within 2 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Palandri, Francesca, Al-Ali, Haifa Kathrin, Guglielmelli, Paola, Zuurman, Mike W., Sarkar, Rajendra, Gupta, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216208/
https://www.ncbi.nlm.nih.gov/pubmed/37345196
http://dx.doi.org/10.3390/cancers15102859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216208/
https://www.ncbi.nlm.nih.gov/pubmed/37345196
http://dx.doi.org/10.3390/cancers15102859

Ejemplares similares